Advarra announced the integration of its electronic institutional review board (eIRB) system, Center for IRB Intelligence (CIRBI), with its Study Collaboration solution, a single-sign-on-enabled software that guides sites through the activation process and improves enrollment planning and tracking. This first-of-its-kind integration creates an automated link between IRB review status and clinical trial startup workflows, giving sponsors and CROs centralized visibility into the status of site activation—from site selection to first-patient-in. Press release.

myTomorrows announced a new partnership with Scout. They aim to streamline and enhance cross-border patient recruitment for clinical trials. This will be achieved by addressing complex financial and logistical arrangements on behalf of patients, families, and caregivers, ensuring they are spared the challenges typically associated with accessing potential pre-approval treatments. While myTomorrows' Patient Navigator team supports patients with initial trial option identification and pre-screening, the Scout Clinical service line offers services such as travel arrangements, expense reimbursements, pre-funded debit cards for out-of-pocket costs, and accommodation support, including short-term lodging and long-term housing for relocated patients and families. Press release.

The Center for Open Science (COS) has unveiled the Replicability Project: Health Behavior (RPHB). This initiative is aimed at reinforcing the corpus of evidence and bolstering the integrity of scientific methodologies within health research disciplines. Over the next few years, the RPHB will focus on evaluating the replicability of a wide array of quantitative health studies that have been published in the past decade, specifically targeting the years 2015 through 2024. By initiating this systematic examination, it is anticipated that the findings will yield crucial insights into the reliability and validity of existing research. Press release.

The Patient-Centered Outcomes Research Institute (PCORI) has announced funding for new patient-centered comparative clinical effectiveness research (CER) studies across a range of conditions. These studies will help provide patients and caregivers with the evidence needed to make more informed health and health care decisions and more effectively manage their health. Press release.

Flatiron Health announced a strategic partnership with Massive Bio to expand patient identification capabilities and improve clinical trial enrollment across the US. This partnership will use Massive Bio’s US-based database on a per-study basis. Access to this source will be leveraged to further identify patients who may not currently be enrolled in clinical trials but are geographically close to an applicable participating site. These patients will be referred to one of Flatiron’s research sites, where they can be onboarded as new patients and considered for potential trial enrollment using Flatiron’s proprietary technology and centralized patient identification services. Press release.

Phesi has launched its self-service Investigator Site Profiler solution. Leveraging the data lake from Phesi’s AI-powered Trial Accelerator platform, Investigator Site Profiler enables heads of feasibility, medical monitors, and study managers to eliminate 20-30% of sites from investigator site lists. Investigator Site Profiler transforms strategic and operational feasibility and enables faster enrolment to substantially reduce the cost of investigator site activation and monitoring processes. Press release.

Veeva Systems announced Veeva SiteVault CTMS, a clinical trial management system for research sites that is integrated with SiteVault eISF and SiteVault eConsent to allow sites to comprehensively manage clinical trials within one main system. Integration with sponsors using Veeva’s Clinical Platform gives sites seamless bidirectional data flow to sponsors to reduce manual processes and increase efficiency. Veeva SiteVault CTMS is planned for initial release in August 2025 and will be free for sites with up to 20 concurrent active studies. Press release.